{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T17:37:51Z","timestamp":1784828271555,"version":"3.55.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,5,22]],"date-time":"2019-05-22T00:00:00Z","timestamp":1558483200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","epilepsybehavior.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Epilepsy &amp; Behavior"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.yebeh.2019.05.021","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T12:10:18Z","timestamp":1563538218000},"page":"110-116","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"PA","title":["Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy"],"prefix":"10.1016","volume":"98","author":[{"given":"Cecilie","family":"Johannessen Landmark","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ida","family":"Fl\u00f8gstad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marte","family":"Syvertsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arton","family":"Baftiu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulla","family":"Enger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeanette","family":"Koht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Svein I.","family":"Johannessen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2019.05.021_bb0005","doi-asserted-by":"crossref","first-page":"S87","DOI":"10.1016\/j.yebeh.2012.11.051","article-title":"Consensus on diagnosis and management of JME: from founder's observations to current trends","volume":"28","author":"Kasteleijn-Nolst Trenite","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0010","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/epi.13613","article-title":"Prevalence of juvenile myoclonic epilepsy in people <30\u202fyears of age\u2014a population-based study in Norway","volume":"58","author":"Syvertsen","year":"2017","journal-title":"Epilepsia"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2019.05.021_bb0015","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1016\/j.yebeh.2012.10.034","article-title":"Clinical aspects of juvenile myoclonic epilepsy","volume":"28","author":"Genton","year":"2013","journal-title":"Epilepsy Behav"},{"issue":"Suppl Pt 1","key":"10.1016\/j.yebeh.2019.05.021_bb0020","first-page":"S23","article-title":"Juvenile myoclonic epilepsy. Epilepsy with impulsive petit mal","volume":"56","author":"Janz","year":"1989","journal-title":"Cleve Clin J Med"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0025","first-page":"254","article-title":"Juvenile myoclonic epilepsy: a 5-year prospective Johannessen SI, Johannessen Landmark C. Antiepileptic drug interactions-basic principles and clinical implications","volume":"8","author":"Panayiotopoulos","year":"2010","journal-title":"Curr Neuropharmacol"},{"issue":"10","key":"10.1016\/j.yebeh.2019.05.021_bb0030","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.addr.2011.10.003","article-title":"Host factors affecting antiepileptic drug delivery-pharmacokinetic variability","volume":"64","author":"Johannessen Landmark","year":"2012","journal-title":"Adv Drug Deliv Rev"},{"issue":"4","key":"10.1016\/j.yebeh.2019.05.021_bb0035","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1684\/epd.2016.0880","article-title":"Dosing strategies for antiepileptic drugs: from a standard dose for all to individualized treatment by implementation of therapeutic drug monitoring","volume":"18","author":"Johannessen Landmark","year":"2016","journal-title":"Epileptic Disord"},{"issue":"1","key":"10.1016\/j.yebeh.2019.05.021_bb0040","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1586\/ern.09.136","article-title":"Drug interactions involving the new second and third generation antiepileptic drugs","volume":"10","author":"Johannessen Landmark","year":"2010","journal-title":"Expert Rev Neurother"},{"issue":"3","key":"10.1016\/j.yebeh.2019.05.021_bb0045","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1111\/epi.12074","article-title":"Updated ILAE evidence review of antiepileptic drug efficacy and effectiveness as initial monotherapy for epileptic seizures and syndromes","volume":"54","author":"Glauser","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0050","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1136\/bmj.e281","article-title":"Diagnosis and management of the epilepsies in adults and children: summary of updated NICE guidance","volume":"e344","author":"Nunes","year":"2012","journal-title":"BMJ"},{"issue":"10","key":"10.1016\/j.yebeh.2019.05.021_bb0055","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1212\/WNL.0000000000001772","article-title":"Dose-dependent teratogenicity of valproate in mono- and polytherapy: an observational study","volume":"85","author":"Tomson","year":"2015","journal-title":"Neurol"},{"issue":"6","key":"10.1016\/j.yebeh.2019.05.021_bb0060","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/S1474-4422(18)30107-8","article-title":"Comparative risk of major congenital malformations with eight different antiepileptic drugs: a prospective cohort of the EURAP registry","volume":"17","author":"Tomson","year":"2018","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0065","author":"European Medicines Agency"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0070","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1111\/epi.12413","article-title":"Risk-taking behavior in juvenile myoclonic epilepsy","volume":"54","author":"Wandschneider","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0075","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1111\/epi.12003","article-title":"Frontal lobe function and structure in juvenile myoclonic epilepsy: a comprehensive review of neuropsychological and imaging data","volume":"53","author":"Wandschneider","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0080","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1007\/s00415-012-6715-z","article-title":"Decision making in juvenile myoclonic epilepsy","volume":"260","author":"Zamarian","year":"2013","journal-title":"J Neurol"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0085","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.yebeh.2018.11.022","article-title":"Psychosocial complications in juvenile myoclonic epilepsy","volume":"90","author":"Syvertsen","year":"2019","journal-title":"Epilepsy Behav"},{"issue":"2","key":"10.1016\/j.yebeh.2019.05.021_bb0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/ane.13042","article-title":"Antiepileptic drug withdrawal in juvenile myoclonic epilepsy","volume":"139","author":"Syvertsen","year":"2019","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0095","series-title":"Adherence to Long Term Therapies \u2014 Evidence for Action","author":"World Health Organization","year":"2003"},{"key":"10.1016\/j.yebeh.2019.05.021_bb5000","doi-asserted-by":"crossref","first-page":"106148","DOI":"10.1016\/j.eplepsyres.2019.05.016","article-title":"Long-term follow-up with therapeutic drug monitoring of antiepileptic drugs in patients with juvenile myoclonic epilepsy","volume":"155","author":"Johannessen Landmark","year":"2019","journal-title":"Epilepsy Res"},{"issue":"5","key":"10.1016\/j.yebeh.2019.05.021_bb0100","first-page":"e58","article-title":"Intentional and non-intentional poor adherence in patients with epilepsy","volume":"60","author":"Henning","year":"2019","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0105","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/ane.12578","article-title":"Discrepancies between physicians' prescriptions and patients' use of antiepileptic drugs","volume":"135","author":"Mevaag","year":"2017","journal-title":"Acta Neurol Scand"},{"issue":"2","key":"10.1016\/j.yebeh.2019.05.021_bb0110","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1093\/fampra\/10.2.201","article-title":"Shared understanding of qualitative research process. Guidelines for the medical researcher","volume":"10","author":"Malterud","year":"1993","journal-title":"Fam Pract"},{"issue":"4","key":"10.1016\/j.yebeh.2019.05.021_bb0115","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.yebeh.2007.03.003","article-title":"Topiramate and valproate in patients with juvenile myoclonic epilepsy: a randomized open-label comparison","volume":"10","author":"Levihson","year":"2007","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0120","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1212\/WNL.62.1.23","article-title":"Systematic screening allows reduction of adverse antiepileptic drug effects: a randomized trial","volume":"62","author":"Gilliam","year":"2014","journal-title":"Neurology"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0125","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.eplepsyres.2017.11.001","article-title":"Utilization of antiepileptic drugs in the elderly vs younger patients with epilepsy and psychiatric comorbidity","volume":"139","author":"Baftiu","year":"2018","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0130","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.yebeh.2018.03.002","article-title":"Juvenile myoclonic epilepsy refractory to treatment in a tertiary referral center","volume":"82","author":"Cacao","year":"2018","journal-title":"Epilepsy Behav"},{"issue":"Suppl. 1","key":"10.1016\/j.yebeh.2019.05.021_bb0135","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1016\/j.yebeh.2013.01.001","article-title":"Management of juvenile myoclonic epilepsy","volume":"28","author":"Crespel","year":"2013","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0140","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1111\/epi.12116","article-title":"Impulsivity and seizure frequency, but not cognitive deficits, impact social adjustment in patients with juvenile myoclonic epilepsy","volume":"54","author":"Moschetta","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0145","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/epi.12886","article-title":"Nonadherence to treatment causing acute hospitalizations in people with epilepsy: an observational, prospective study","volume":"56","author":"Samsonsen","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0150","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.yebeh.2017.11.039","article-title":"Patients' perspectives on management and barriers of regular antiepileptic drug intake","volume":"79","author":"May","year":"2018","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0155","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.yebeh.2018.12.031","article-title":"Fetal antiepileptic drug exposure and learning and memory functioning at 6\u202fyears of age: the NEAD prospective observational study","volume":"92","author":"Cohen","year":"2019","journal-title":"Epilepsy Behav"},{"key":"10.1016\/j.yebeh.2019.05.021_bb0160","doi-asserted-by":"crossref","first-page":"e72","DOI":"10.1111\/epi.12621","article-title":"SUDEP and epilepsy-related mortality in pregnancy","volume":"55","author":"Edey","year":"2014","journal-title":"Epilepsia"},{"issue":"8","key":"10.1016\/j.yebeh.2019.05.021_bb0165","doi-asserted-by":"crossref","first-page":"e173","DOI":"10.1111\/epi.13437","article-title":"Withdrawal of valproic acid treatment during pregnancy and seizure outcome: observations from EURAP","volume":"57","author":"Tomson","year":"2016","journal-title":"Epilepsia"}],"container-title":["Epilepsy &amp; Behavior"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019304056?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525505019304056?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T18:27:49Z","timestamp":1761503269000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525505019304056"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":34,"alternative-id":["S1525505019304056"],"URL":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.021","relation":{},"ISSN":["1525-5050"],"issn-type":[{"value":"1525-5050","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment and challenges with antiepileptic drugs in patients with juvenile myoclonic epilepsy","name":"articletitle","label":"Article Title"},{"value":"Epilepsy & Behavior","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.yebeh.2019.05.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}